Kuros Biosciences reports a 163% increase in MagnetOs sales and a 153% rise in overall medical device sales in 2023.
Kuros Biosciences, a bone graft tech leader, reports a 163% increase in MagnetOs sales to CHF 31.7M in 2023, along with a 153% increase in overall medical device sales to CHF 33.6M. The company has treated 25,000 patients, resulting in a positive EBITDA of CHF 6.8M for the Medical Devices product segment in 2023. Kuros anticipates further growth and aims for positive single-digit EBITDA in 2024.
March 13, 2024
5 Articles